Risvutatug rezetecan

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline, Nader Sanai

Conditions

Brain MetastasasesGastrointestinal NeoplasmsGlioblastoma (GBM)Neoplasms, Lung

Early Phase 1

A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases

RecruitingNCT07268053

Nader SanaiBrain Metastasases, Glioblastoma (GBM)

Start: 2026-02-11End: 2029-07-01Target: 15Updated: 2026-03-06

Phase 1

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

RecruitingNCT06885034

GlaxoSmithKlineGastrointestinal Neoplasms

Start: 2025-06-11End: 2029-01-09Target: 451Updated: 2026-08-03

A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)

Not yet recruitingNCT07602855

GlaxoSmithKlineNeoplasms, Lung

Start: 2026-09-08End: 2029-12-21Target: 184Updated: 2026-09-10

Related Papers

A phase 1b/2, multicenter, open-label study to evaluate the efficacy and safety of GSK5764227 (GSK’227), alone and in combination in patients with previously treated advanced unresectable or metastatic gastrointestinal solid tumors.

Journal of Clinical Oncology2026-01-10